60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
2.660
+0.360 (15.65%)
At close: May 29, 2025, 4:00 PM
2.740
+0.080 (3.00%)
After-hours: May 29, 2025, 7:12 PM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $256.28K in the quarter ending March 31, 2025, with 75.42% growth. This brings the company's revenue in the last twelve months to $802.32K, up 118.37% year-over-year. In the year 2024, 60 Degrees Pharmaceuticals had annual revenue of $681.35K with 168.70% growth.
Revenue (ttm)
$802.32K
Revenue Growth
+118.37%
P/S Ratio
2.43
Revenue / Employee
$267,441
Employees
3
Market Cap
3.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | 2.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SXTP News
- 14 days ago - 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results - GlobeNewsWire
- 5 weeks ago - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - GlobeNewsWire
- 7 weeks ago - Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 - GlobeNewsWire
- 7 weeks ago - Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 3 months ago - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewsWire
- 3 months ago - Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - GlobeNewsWire
- 4 months ago - 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire